CHARLES CITY — Pfizer Animal Health in Charles City is now named Zoetis.

Pfizer Inc. announced on Feb. 1, that its former animal health business unit, now a standalone company named Zoetis, began trading on the New York Stock Exchange under the ticker symbol “ZTS.”

“This is a proud moment for all Zoetis and Pfizer employees,” said Ian Read, chairman and chief executive officer of Pfizer, in a news release. “With the Zoetis initial public offering, we are creating the largest standalone company fully devoted to animal health medicines and vaccines. For Pfizer, we are better positioned to focus on our core business as an innovative biopharmaceutical company, by unlocking value from the animal health business that will return value to Pfizer shareholders.”

Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines for livestock and companion animals. Pfizer announced in 2012 that it would pursue an initial public offering (IPO) of a minority ownership stake in its animal health business unit as part of its long-term strategy to focus on the company’s core biopharmaceuticals business.

“Since 1952, our animal health business has served the needs of those who raise and care for animals with high quality medicines and vaccines. Now, as Zoetis, it is well positioned to pursue the growth strategies that will enhance its global reach and drive further commercial success. We congratulate our Zoetis colleagues on this important milestone,” said Read.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.